ESR1 and breast carcinoma: Patients with hormone-receptor positive breast cancer are encouraged to undergo endocrine therapy, with a selective estrogen receptor modulator (tamoxifen) being administered to those premenopausal, and an aromatase inhibitor being given to those postmenopausal.